Arun B. Jesudian, MD
PeerArun B. Jesudian, MD
PeerPatricia P. Bloom, MD
PeerRobert Rahimi, MD, MSCR
PeerPatricia P. Bloom, MD
PeerWhat Is the Evidence Supporting CLDN18.2 Targeting in Frontline Management of G/GEJ Cancers
Samuel J. Klempner, MD
PeerWhat Is the Current Standard for First-Line Treatment of Metastatic HER2-Negative G/GEJ Cancers?
Yelena Janjigian, MD
PeerYelena Janjigian, MD
PeerClaudin18.2: An Emerging Biomarker and Its Significance as a Therapeutic Target in G/GEJ Cancers
Samuel J. Klempner, MD
Peer